Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

May 6, 2026 8:05 AM

Aptevo Therapeutics Inc. (Nasdaq:APVO) today reported new clinical results from its RAINIER frontline acute myeloid leukemia (AML) trial. The Company is on track to complete the Phase 1b dose-optimization trial and select the recommended Phase 2 dose (RP2D) this year. As with the current study, the Phase 2 trial will dose mipletamig in combination with venetoclax and azacitidine.Across 31 evaluable frontline AML patients treated to date...

Read more

Dr. Ran Rubinstein Introduces Renuva(R): A Breakthrough Non-Surgical Fat Restoration Treatment in New York and New Jersey

May 6, 2026 8:00 AM

Ran Y. Rubinstein, MD, a double board-certified facial plastic surgeon serving patients throughout New York and New Jersey, has announced the addition of Renuva® to his practice's non-surgical treatment menu. The injectable treatment is now available at Laser & Cosmetic Surgery Specialists in Newburgh, NY and Rubinstein Plastic Surgery Center in Montvale, NJ, offering patients in the Hudson Valley and Bergen County a new option for addressing...

Read more

Mach7 Appoints Brian Wehrle as Chief Technology Officer

May 6, 2026 6:00 AM

Mach7 Technologies, a leading provider of enterprise imaging solutions, today announced the appointment of Brian Wehrle as Chief Technology Officer (CTO). In this role, Wehrle will lead the company's global engineering and technology strategy, accelerating innovation across Mach7's enterprise imaging platform.Wehrle brings more than 25 years of experience in healthcare technology, software engineering, and product development. Most recently, he...

Read more

Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference

May 6, 2026 6:00 AM

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the 2026 Bank of America Health Care Conference on Wednesday, May 13, 2026, at 3:00 pm PT. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar...

Read more

Spago Nanomedical's Phase I/IIa study Tumorad-01 Meets a Primary Endpoint and Provides Further Visible Tumor Uptake

May 6, 2026 5:10 AM

Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - Spago Nanomedical AB (publ) announced today that the independent Data Monitoring Committee (DMC) of the Tumorad-01 study declared that a primary endpoint, identifying the maximum tolerated dose, has been met and recommends that an additional two patients are enrolled at the dose level of 15 MBq/kg to provide a basis for defining a recommended phase II dose and completion of the phase I part of the...

Read more

Invitation to the Presentation of Cantargia's Interim Report for Q1 2026

May 6, 2026 4:20 AM

Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's interim report for Q1 2026 on Tuesday, May 19, 2026, at 07:00 a.m. CEST.In conjunction to the report, investors, analysts, and media are invited to an audiocast with teleconference (in English) on May 19, at 3:00 p.m. CEST, where Cantargia's CEO Hilde Steineger, and CFO Patrik Renblad, will present Cantargia and comment on the report, followed by a Q&A-session.If you wish to...

Read more

New scientific Article Published on TrkA-NAM ACD137 Against Osteoarthritic Pain

May 6, 2026 4:20 AM

AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that a scientific article has been published on the preclinical characterization of ACD137, the lead drug candidate in the TrkA-NAM pain project.The scientific article, titled Analgesic, anti-inflammatory and joint protective effects of ACD137, a...

Read more

IRLAB Publishes Interim Report for The Period January - March 2026

May 6, 2026 1:20 AM

IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that the interim report for the period January-March 2026, has been published.KEY HIGHLIGHTS DURING AND AFTER THE FIRST QUARTERIn January, IRLAB entered into a collaboration agreement with the Danish biotech company Biomia ApS to evaluate Biomia's drug candidates using IRLAB's research platform, the...

Read more

Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation

May 5, 2026 6:00 PM

Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that Inka Health Corp. ("Inka Health"), the Company's wholly owned subsidiary, has started a collaborative research agreement (the "Agreement" or "Project" or "Work") with GlaxoSmithKline LLC ("GSK"). Under the Agreement, Inka Health and GSK intend to collaborate to develop real-world data-driven methodologies aimed at...

Read more

Big Cannabis Sold You a Lie. Now the Federal Government Is Giving It to Your Grandparents.

May 5, 2026 5:35 PM

They called it medicine.They said it could treat your anxiety, your pain, your PTSD, your insomnia, your opioid addiction, your cancer, your irritable bowel syndrome, your grief, your boredom, your sadness, and your shyness.They built billion dollar companies on those claims. They hired lobbyists, funded public relations campaigns, and placed their products in gleaming dispensaries designed to look like Apple Stores - all while knowing,...

Read more

Viemed Healthcare Announces First Quarter 2026 Financial Results

May 5, 2026 5:00 PM

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, announced today that it has reported its financial results for the three months ended March 31, 2026, and updated guidance for the full year ending December 31, 2026.Operational highlights (all dollar amounts are USD):Net revenues for the quarter ended March 31, 2026 were...

Read more

Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 5, 2026 4:05 PM

Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update."The first quarter of 2026 marked a series of landmark achievements for Protagonist, highlighted by the U.S. approval of ICOTYDE, FDA granting Priority Review for rusfertide, and advancement of our highly differentiated and fully-owned peptides PN-881 and PN-477,"...

Read more

Omni-Biotic Ranked #1 Probiotic Brand in Europe, Reflecting Strong Consumer Trust and Scientific Foundation

May 5, 2026 12:10 PM

Omni-Biotic U.S. announced today that Omni-Biotic has been ranked the #1 probiotic brand in Europe, based on IQVIA Consumer Health Customized Insight Study data. This distinction reflects the brand's leading position across European markets and underscores its continued expansion in the United States.In an increasingly competitive probiotic category, Omni-Biotic's leadership is driven by strong consumer adoption, practitioner endorsement, and a...

Read more

MilliporeSigma Receives 2026 Environment+Energy Leader Spotlight Award

May 5, 2026 11:00 AM

The 2026 Environment+Energy Leader Awards have recognized MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, for its commitment to preparing scientists to address sustainability through chemistry.The company received a Spotlight Award in the Collaboration category for its partnership with Beyond Benign, a leading green chemistry education non-profit devoted to empowering educators to transform chemistry...

Read more

Medical Care Technologies Inc. (OTC PINK:MDCE) Advances AI Platform Accuracy for Early Melanoma Detection

May 5, 2026 10:15 AM

Medical Care Technologies Inc. (OTC PINK:MDCE) ("MDCE" or the "Company"), an emerging developer of AI-powered health and wellness technologies, today announced that it is actively evaluating and integrating new advances in artificial intelligence to support the development of high accuracy dermatological imaging solutions focused on early-stage skin condition detection. Building upon its patent-pending imaging platform, the Company is...

Read more

Utah Medical Products, Inc. Announces Quarterly Dividend

May 5, 2026 10:00 AM

Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty-one cents ($.31) per share of common stock payable on July 3, 2026 to stockholders of record at the close of business on June 17, 2026. This is a 1.6% increase over the dividend declared in the same quarter of the prior year.Utah Medical Products, Inc., with particular interest in health care for women and their babies,...

Read more

RADIESSE(R) Receives FDA Approval for Décolleté Wrinkles as Dr. Rubinstein Provides Proven, FDA-Approved Solutions in New York and New Jersey

May 5, 2026 8:00 AM

Merz Aesthetics has announced that the FDA has approved RADIESSE® for the treatment of wrinkles in the décolleté area in patients 22 years of age or older - making it the first and only biostimulator in the United States approved for both the face and the body. This marks the fourth FDA-approved indication for RADIESSE, further cementing its position as one of the most versatile and clinically supported injectable treatments available in...

Read more

MEDIA ADVISORY: Grand Opening and Community Blood Drive Address Critical Local Need

May 5, 2026 8:00 AM

Advanced Health will host a community open house and blood drive on May 19, 2026, celebrating the opening of its new primary care office and reinforcing its commitment to improving access to high-quality, patient-centered care for the Greenville community.EVENT DETAILSWhat: Grand Opening + Community Blood DriveWhen: May 19, 2026 | 4 - 6 pmWhere: 56 Pointe Circle, Suite 200 Greenville SC 29615Who: Open to the public; media invited Offering...

Read more

AMC Health Appoints Sol Babani and Symbiosis Advisors as Strategic Advisor to Its Decentralized Clinical Trial Service Line

May 5, 2026 8:00 AM

AMC Health today announced the appointment of Sol Babani, Founder and CEO of Symbiosis Advisors, as Strategic Advisor to its newly established Decentralized Clinical Trial (DCT) service line. Babani will work closely with CEO Nesim Bildirici and Keith Tode, Executive Vice President of Decentralized Clinical Trials, to grow and operationalize AMC Health's DCT platform as it expands its modular operating partner offering to biopharmaceutical...

Read more

CBD Life Sciences Inc. (CBDL) Announces Launch of CBD Pouches Nicotine Free

May 5, 2026 7:00 AM

CBD Life Sciences Inc. (OTCID:CBDL) CBD Life Sciences Inc. is proud to announce our latest product CBD Pouches that are Nicotine Free. Our Tins Pouches are made for anyone looking for an easy, hassle-free way to enjoy the benefits without overcomplicating things. They offer a familiar chew-style experience with an added sense of relaxation-ideal for unwinding or making it through your day with less stress. Crafted from natural ingredients, these...

Read more